CRISPR Therapeutics (CRSP)
(Real Time Quote from BATS)
$55.53 USD
-1.43 (-2.51%)
Updated May 16, 2024 01:52 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 201 - 209 ( 209 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
3Q19 - Full Steam Ahead. Data Possible at ASH.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
CRISPR Engineering Could Provide Immune-Evasive Cell Therapy for Diabetes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
2Q19 Update - Raising Our PT to $65/ Share As CTX110 Enters The Clinic
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Momentum Builds With Two IND Approvals. Initiating at Buy. $50 PT.
Provider: Roth Capital Partners, Inc.
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Momentum Builds With Two IND Approvals. Initiating at Buy. $50 PT.
Provider: Roth Capital Partners, Inc.